Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson’s Disease
Competitor Analysis: Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease
The Competitive Intelligence report about Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease provides a competitor analysis in the discovery and development pipeline of novel therapeutics for treatment of Parkinson's Disease (PD). Alpha-synuclein and leucine-rich repeat kinase 2 (LRRK2) represent molecular targets for novel drug candidates to treat PD. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Of the various genetic factors contributing to the pathogenesis of Parkinson's disease, only mutations in alpha-synuclein andLRRK2 genes cause clinical and neuropathological phenotypes closely resembling the sporadic cases. Therefore, studying the pathophysiological functions of these two PD-related genes is particularly informative in understanding the underlying molecular pathogenic mechanism of the disease. PD-related missense and multiplication mutations in ?-synunclein may cause both early- and late-onset PD, whereas various PD-related LRRK2 missense mutations may contribute to the more common late-onset PD.
The report provides a compilation of active projects in research and development for treatment of Parkinson's disease based on inhibitors of the molecular targets alpha-synuclein and LRRK2 including small molecules, antibodies, vaccines and RNAi. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The Competitive Intelligence report about Alpha Synuclein and LRRK2 Inhibitors - Novel Drug Candidates for Parkinson's Disease provides a competitor analysis in the discovery and development pipeline of novel therapeutics for treatment of Parkinson's Disease (PD). Alpha-synuclein and leucine-rich repeat kinase 2 (LRRK2) represent molecular targets for novel drug candidates to treat PD. Purchase of the pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Of the various genetic factors contributing to the pathogenesis of Parkinson's disease, only mutations in alpha-synuclein andLRRK2 genes cause clinical and neuropathological phenotypes closely resembling the sporadic cases. Therefore, studying the pathophysiological functions of these two PD-related genes is particularly informative in understanding the underlying molecular pathogenic mechanism of the disease. PD-related missense and multiplication mutations in ?-synunclein may cause both early- and late-onset PD, whereas various PD-related LRRK2 missense mutations may contribute to the more common late-onset PD.
The report provides a compilation of active projects in research and development for treatment of Parkinson's disease based on inhibitors of the molecular targets alpha-synuclein and LRRK2 including small molecules, antibodies, vaccines and RNAi. Competitor projects are listed in a tabular format providing information on:
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Company
- Product Category
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Alpha Synuclein Inhibitors
LRRK2 Inhibitors
Corporate R&D Pipelines of alpha Synuclein and LRRK2 Inhibitors
LRRK2 Inhibitors
Corporate R&D Pipelines of alpha Synuclein and LRRK2 Inhibitors
